TCF4 and Huntington disease: Moreover, WNT ligands (WNT3, 4,6, 7B, 10A), effectors (TCF3 and TCF4), and downstream targets (AXIN2 and APDCC1) are upregulated on iPSCs-derived microvascular cells from HD patients and WNT inhibition prevented the angiogenic deficits and BBB impairment in HD models [176].